Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Само за регистроване кориснике
2016
Аутори
Bajić, VladanSudar-Milovanović, Emina
Potparević, Biljana
Živković, Lada
Miliccivc, Zorka
Stanimirović, Julijana
Bogdanović, Nikola
Isenović, Esma
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Извор:
Current Pharmaceutical Analysis, 2016, 12, 2, 82-90Издавач:
- Bentham Science Publ Ltd, Sharjah
Финансирање / пројекти:
- Хормонска регулација експресије и активности азот оксид синтазе и натријум-калијумове пумпе у експерименталним моделима инсулинске резистенције, дијабетеса и кардиоваскуларних поремећаја (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/1573412911666150611184740
ISSN: 1573-4129
WoS: 000374885700001
Scopus: 2-s2.0-84961637983
Институција/група
PharmacyTY - JOUR AU - Bajić, Vladan AU - Sudar-Milovanović, Emina AU - Potparević, Biljana AU - Živković, Lada AU - Miliccivc, Zorka AU - Stanimirović, Julijana AU - Bogdanović, Nikola AU - Isenović, Esma PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2591 AB - Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD. PB - Bentham Science Publ Ltd, Sharjah T2 - Current Pharmaceutical Analysis T1 - Treatment of Alzheimer's Disease: Classical Therapeutic Approach VL - 12 IS - 2 SP - 82 EP - 90 DO - 10.2174/1573412911666150611184740 ER -
@article{ author = "Bajić, Vladan and Sudar-Milovanović, Emina and Potparević, Biljana and Živković, Lada and Miliccivc, Zorka and Stanimirović, Julijana and Bogdanović, Nikola and Isenović, Esma", year = "2016", abstract = "Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.", publisher = "Bentham Science Publ Ltd, Sharjah", journal = "Current Pharmaceutical Analysis", title = "Treatment of Alzheimer's Disease: Classical Therapeutic Approach", volume = "12", number = "2", pages = "82-90", doi = "10.2174/1573412911666150611184740" }
Bajić, V., Sudar-Milovanović, E., Potparević, B., Živković, L., Miliccivc, Z., Stanimirović, J., Bogdanović, N.,& Isenović, E.. (2016). Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis Bentham Science Publ Ltd, Sharjah., 12(2), 82-90. https://doi.org/10.2174/1573412911666150611184740
Bajić V, Sudar-Milovanović E, Potparević B, Živković L, Miliccivc Z, Stanimirović J, Bogdanović N, Isenović E. Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis. 2016;12(2):82-90. doi:10.2174/1573412911666150611184740 .
Bajić, Vladan, Sudar-Milovanović, Emina, Potparević, Biljana, Živković, Lada, Miliccivc, Zorka, Stanimirović, Julijana, Bogdanović, Nikola, Isenović, Esma, "Treatment of Alzheimer's Disease: Classical Therapeutic Approach" in Current Pharmaceutical Analysis, 12, no. 2 (2016):82-90, https://doi.org/10.2174/1573412911666150611184740 . .